Yan MD - Ipsen SA VP Area
| I7G Stock | EUR 107.30 0.20 0.19% |
Insider
Yan MD is VP Area of Ipsen SA
| Age | 56 |
| Phone | 33 1 58 33 50 00 |
| Web | https://www.ipsen.com |
Ipsen SA Management Efficiency
The company has return on total asset (ROA) of 0.1026 % which means that it generated a profit of $0.1026 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1944 %, meaning that it generated $0.1944 on every $100 dollars invested by stockholders. Ipsen SA's management efficiency ratios could be used to measure how well Ipsen SA manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Kevin Mannix | Teva Pharmaceutical Industries | N/A | |
| Deepak MBA | Dr Reddys Laboratories | 48 | |
| Gunupati BE | Dr Reddys Laboratories | 63 | |
| Steven Esq | Catalent | 60 | |
| Takeshi Shiota | Shionogi Co | N/A | |
| Salvatore Alesci | Takeda Pharmaceutical | N/A | |
| Constantine Saroukos | Takeda Pharmaceutical | 52 | |
| William Price | Zoetis Inc | N/A | |
| Haruo Naito | Eisai Co | 76 | |
| Eliyahu Kalif | Teva Pharmaceutical Industries | 50 | |
| Nadeem Sarwar | Eisai Co | N/A | |
| Haruhiko Hirate | Takeda Pharmaceutical | 66 | |
| Amir Weiss | Teva Pharmaceutical Industries | 46 | |
| Teruyuki Masaka | Eisai Co | 45 | |
| Sayoko Sasaki | Eisai Co | 55 | |
| Eric Drape | Teva Pharmaceutical Industries | 61 | |
| Tatsuyuki Yasuno | Eisai Co | 55 | |
| Thomas Larsen | Swedish Orphan Biovitrum | 49 | |
| Sanjay BTech | Dr Reddys Laboratories | 55 | |
| Pablo Mora | Swedish Orphan Biovitrum | 55 | |
| Jeannette Astorga | Zoetis Inc | 48 | |
Management Performance
Ipsen SA Leadership Team
Elected by the shareholders, the Ipsen SA's board of directors comprises two types of representatives: Ipsen SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ipsen. The board's role is to monitor Ipsen SA's management team and ensure that shareholders' interests are well served. Ipsen SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ipsen SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Aidan Murphy, Ex Operations | ||
| David Loew, CEO MD | ||
| Gwenan White, Ex Affairs | ||
| Craig Marks, VicePres Relations | ||
| Francois Garnier, Gen Affairs | ||
| Yan MD, VP Area | ||
| Aymeric Chatelier, Ex CFO | ||
| Regis Mulot, Ex Officer | ||
| Stephan Gagne, Head Office | ||
| Dominique Bery, Head Baltics |
Ipsen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ipsen SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.19 | |||
| Return On Asset | 0.1 | |||
| Profit Margin | 0.21 % | |||
| Operating Margin | 0.28 % | |||
| Current Valuation | 8.46 B | |||
| Shares Outstanding | 82.63 M | |||
| Shares Owned By Insiders | 57.12 % | |||
| Shares Owned By Institutions | 20.19 % | |||
| Price To Earning | 20.55 X | |||
| Price To Book | 2.88 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Ipsen Stock
Ipsen SA financial ratios help investors to determine whether Ipsen Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ipsen with respect to the benefits of owning Ipsen SA security.